Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
about
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingEfficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SLixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.Lixisenatide.Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.
P2860
Q26852590-27A40D9D-662E-4EEE-9CA7-1C9FDAC1D6E6Q26992979-CCBBA718-337F-4A4C-A5CE-2C3C42FF22CEQ35192193-D078D691-74BE-44E2-80C6-A7B1CB10DED2Q35994230-46EFEA53-502B-4707-A6DF-06AFD91E1AC4Q36554216-09906FDD-9A1C-47F4-B6FC-E634C5AB3390Q38616170-139B473E-AF0E-4603-AF34-7C2A7C793351Q38711727-A3FA6385-881D-4711-A943-8D01D358DE83Q39054666-16B611B8-F45C-4E88-B945-2007EAE2A1BBQ39337620-2358F705-81E9-4472-87EC-55B6AACD0DF7Q47151922-F0B08032-F949-40A4-A271-5F9C9FA998D1Q52568454-5A461F5B-3424-409F-B3CE-8FF770CF7A20
P2860
Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@ast
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@en
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@nl
type
label
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@ast
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@en
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@nl
prefLabel
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@ast
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@en
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@nl
P2093
P2860
P356
P1476
Lixisenatide resensitizes the ...... diabetes and healthy subjects.
@en
P2093
P2860
P304
P356
10.1111/DOM.12278
P577
2014-03-25T00:00:00Z